Clinical Effectiveness of Beta-Blockers in Heart Failure. Findings From the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) Registry

Journal of the American College of Cardiology

Volumn 53, Issue 2, 2009, Pages 184-192

  Hernandez, Adrian F ^a,b   Hammill, Bradley G ^a   O'Connor, Christopher M ^a,b   Schulman, Kevin A ^a,b   Curtis, Lesley H ^a,b   Fonarow, Gregg C ^c  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

adrenergic beta antagonists; heart failure; mortality patient readmission

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN; SODIUM;

AGED; ANEMIA; ANGIOCARDIOGRAPHY; ARTICLE; ARTIFICIAL VENTILATION; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COMORBIDITY; CONFIDENCE INTERVAL; CREATININE BLOOD LEVEL; DEFIBRILLATOR; DEPRESSION; DIABETES MELLITUS; DIAGNOSTIC TEST; DRUG EFFICACY; FEMALE; HAZARD RATIO; HEART ATRIUM ARRHYTHMIA; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE OVERLOAD; HEMOGLOBIN BLOOD LEVEL; HOSPITAL READMISSION; HUMAN; HYPERLIPIDEMIA; LEG EDEMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; THYROID DISEASE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; FEMALE; HEART FAILURE; HUMANS; MALE; PATIENT READMISSION; REGISTRIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 58149097941     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.09.031     Document Type: Article

References (26)

1. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 (2008) e25-e146
2. Krumholz H.M., Parent E.M., Tu N., et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 157 (1997) 99-104
3. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 (2005) e1-e82
4. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
5. CIBS Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999) 9-13
6. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
7. Heiat A., Gross C.P., and Krumholz H.M. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 162 (2002) 1682-1688
8. Lee D.S., Mamdani M.M., Austin P.C., et al. Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000. Am J Med 116 (2004) 581-589
9. Ezekowitz J., McAlister F.A., Humphries K.H., et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 44 (2004) 1587-1592
10. Lee D.S., Tu J.V., Juurlink D.N., et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 294 (2005) 1240-1247
11. Patel P., White D.L., and Deswal A. Translation of clinical trial results into practice: temporal patterns of beta-blocker utilization for heart failure at hospital discharge and during ambulatory follow-up. Am Heart J 153 (2007) 515-522
12. Packer M., Bristow M.R., Cohn J.N., et al., U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996) 1349-1355
13. Fonarow G.C., Abraham W.T., Albert N.M., et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J 148 (2004) 43-51
14. Fonarow G.C., Abraham W.T., Albert N.M., et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med 167 (2007) 1493-1502
15. Gheorghiade M., Abraham W.T., Albert N.M., et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296 (2006) 2217-2226
16. Fonarow G.C., Abraham W.T., Albert N.M., et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 297 (2007) 61-70
17. Curtis L.H., Hernandez A.F., Greiner M.A., Fonarow G.C., and Schulman K.A. Validity of a national heart failure quality of care registry: comparison of Medicare patients in OPTIMIZE-HF versus non-OPTIMIZE-HF hospitals (abstr). Circulation 115 (2007) e595
18. Fonarow G.C., Abraham W.T., Albert N.M., et al. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 153 (2007) 82.e1-82.e11
19. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1998) 1141-1154
20. Anstrom K.J., and Tsiatis A.A. Utilizing propensity scores to estimate causal treatment effects with censored time-lagged data. Biometrics 57 (2001) 1207-1218
21. Cole S.R., and Hernan M.A. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed 75 (2004) 45-49
22. Weitzen S., Lapane K.L., Toledano A.Y., Hume A.L., and Mor V. Principles for modeling propensity scores in medical research: a systematic literature review. Pharmacoepidemiol Drug Saf 13 (2004) 841-853
23. Flather M.D., Shibata M.C., Coats A.J., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005) 215-225
24. Go A.S., Yang J., Gurwitz J.H., Hsu J., Lane K., and Platt R. Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure. Am J Cardiol 100 (2007) 690-696
25. Fonarow G.C., Abraham W.T., Albert N.M., et al. Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF. J Card Fail 13 (2007) 722-731
26. Henkel D.M., Redfield M.M., Weston S.A., Gerber Y., and Roger V.L. Death in heart failure: a community perspective. Circulation: Heart Failure 1 (2008) 91-97